New imaging agent could spot returning prostate cancer earlier

NCT ID NCT04838613

Completed Diagnosis Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 study tested a new radioactive tracer called [18F]CTT1057 for PET/CT scans in 190 men with prostate cancer whose PSA levels were rising after initial treatment. The goal was to see if the tracer could accurately locate where the cancer had returned. Participants received both the new tracer and a standard one for comparison.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]CTT1057 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could provide a more accurate way to detect where prostate cancer has returned after initial treatment, helping guide further therapy.
What could go wrong: This is a diagnostic study, not a treatment. The tracer may not be more effective than existing options, and false positives or negatives are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate neoplasm Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PROSTATIC NEOPLASMS RECURRENCE

Contacts and locations

Locations

Explorer Molecular Imaging center

Sacramento, California, 95816, United States
Novartis Investigative Site

Marseille, 13273, France
Novartis Investigative Site

Marseille, 13885, France
Novartis Investigative Site

Nîmes, 30029, France
Novartis Investigative Site

Pierre-Bénite, 69495, France
Novartis Investigative Site

Saint-Priest-en-Jarez, 42270, France
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Barcelona, 08041, Spain
Novartis Investigative Site

Valencia, 46026, Spain
Novartis Investigative Site

Geneva, 1211, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.